Neuronal substrates and functional consequences of prenatal cannabis exposure

European Child and Adolescent Psychiatry

Volumn 23, Issue 10, 2014, Pages 931-941

  Calvigioni, Daniela ^a,b   Hurd, Yasmin L ^c   Harkany, Tibor ^a,b   Keimpema, Erik ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Medical University of Vienna   (Austria)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Endocannabinoid; Foetal development; Neuropsychiatric disease; THC

Indexed keywords

CANNABIS; ENDOCANNABINOID;

ANIMAL; BRAIN; CANNABIS ADDICTION; CHEMICALLY INDUCED; COMPLICATION; DEVELOPMENTAL DISORDER; DRUG EFFECTS; ENVIRONMENTAL EXPOSURE; FEMALE; FETOMATERNAL TRANSFUSION; FETUS; HUMAN; MENTAL DISEASE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; PRENATAL EXPOSURE; SIGNAL TRANSDUCTION; TOXICITY;

ANIMALS; BRAIN; CANNABIS; DEVELOPMENTAL DISABILITIES; ENDOCANNABINOIDS; FEMALE; FETUS; HUMANS; MARIJUANA ABUSE; MATERNAL EXPOSURE; MATERNAL-FETAL EXCHANGE; MENTAL DISORDERS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; SIGNAL TRANSDUCTION;

EID: 84921713751     PISSN: 10188827     EISSN: 1435165X     Source Type: Journal    
DOI: 10.1007/s00787-014-0550-y     Document Type: Review

References (110)

1. UNODC (2011) World Drug Report
2. European Monitoring Centre for Drugs and Drug Addiction E (2013) European drug report. Trends and Development
3. European Monitoring Centre for Drugs and Drug Addiction E (2013) Synthetic cannabinoids in Europe
4. European Monitoring Centre for Drugs and Drug Addiction E (2012) Legal topic overviews: possession of cannabis for personal use
5. Grotenhermen F (2004) Pharmakologie, Toxikologie und therapeutisches Potential. 2nd edn. Hans Huber, Göttingen
6. Atwood BK et al (2010) JWH018, a common constituent of ‘Spice’ herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol 160(3):585–593
7. Atwood BK et al (2011) CP47, 497-C8 and JWH073, commonly found in ‘Spice’ herbal blends, are potent and efficacious CB(1) cannabinoid receptor agonists. Eur J Pharmacol 659(2–3):139–145
8. Zawilska JB, Wojcieszak J (2013) Spice/K2 drugs: more than innocent substitutes for marijuana. Int J Neuropsychopharmacol 17(3):509–525
9. Fantegrossi WE et al (2013) Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Delta-THC: mechanism underlying greater toxicity. Life Sci 97(1):45–54
10. SAMHSA (2011) Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings
11. SAMHSA (2013) 2012 National Survey on Drug Use and Health (NSDUH)
12. Wingo PA et al (2011) Recent changes in the trends of teen birth rates, 1981–2006. J Adolesc Health 48(3):281–288
13. SAMHSA (2010) Pregnant teen admissions to substance abuse treatment: 1992 and 2007
14. Huizink AC (2013) Prenatal cannabis exposure and infant outcomes: overview of studies. Prog Neuropsychopharmacol Biol Psychiatry 52:45–52. doi:10.1016/j.pnpbp.2013.09.014
15. Jutras-Aswad D et al (2009) Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome. Eur Arch Psychiatry Clin Neurosci 259(7):395–412
16. Fried PA (2002) Conceptual issues in behavioral teratology and their application in determining long-term sequelae of prenatal marihuana exposure. J Child Psychol Psychiatry 43(1):81–102
17. Morris CV et al (2011) Molecular mechanisms of maternal cannabis and cigarette use on human neurodevelopment. Eur J Neurosci 34(10):1574–1583
18. Driscoll CD, Streissguth AP, Riley EP (1990) Prenatal alcohol exposure: comparability of effects in humans and animal models. Neurotoxicol Teratol 12(3):231–237
19. Knopik VS (2009) Maternal smoking during pregnancy and child outcomes: real or spurious effect? Dev Neuropsychol 34(1):1–36
20. Linnet KM et al (2003) Maternal lifestyle factors in pregnancy risk of attention deficit hyperactivity disorder and associated behaviors: review of the current evidence. Am J Psychiatry 160(6):1028–1040
21. Rice D, Barone S Jr (2000) Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environ Health Perspect 108(Suppl 3):511–533
22. Gross C, Hen R (2004) The developmental origins of anxiety. Nat Rev Neurosci 5(7):545–552
23. Lyon M et al (1989) Fetal neural development and schizophrenia. Schizophr Bull 15(1):149–161
24. Thompson BL, Levitt P, Stanwood GD (2009) Prenatal exposure to drugs: effects on brain development and implications for policy and education. Nat Rev Neurosci 10(4):303–312
25. Rogers JM (2009) Tobacco and pregnancy. Reprod Toxicol 28(2):152–160
26. Nielsen A et al (2006) Maternal smoking predicts the risk of spontaneous abortion. Acta Obstet Gynecol Scand 85(9):1057–1065
27. Abbott LC, Winzer-Serhan UH (2012) Smoking during pregnancy: lessons learned from epidemiological studies and experimental studies using animal models. Crit Rev Toxicol 42(4):279–303
28. El Marroun H et al (2014) Prenatal tobacco exposure and brain morphology: a prospective study in young children. Neuropsychopharmacology 39(4):792–800
29. Roy TS, Sabherwal U (1994) Effects of prenatal nicotine exposure on the morphogenesis of somatosensory cortex. Neurotoxicol Teratol 16(4):411–421
30. Roy TS et al (1998) Nicotine evokes cell death in embryonic rat brain during neurulation. J Pharmacol Exp Ther 287(3):1136–1144
31. Bell SH et al (2010) The remarkably high prevalence of epilepsy and seizure history in fetal alcohol spectrum disorders. Alcohol Clin Exp Res 34(6):1084–1089
32. Grotenhermen F (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42(4):327–360
33. Hurd YL et al (2005) Marijuana impairs growth in mid-gestation fetuses. Neurotoxicol Teratol 27(2):221–229
34. Dinieri JA, Hurd YL (2012) Rat models of prenatal and adolescent cannabis exposure. Methods Mol Biol 829:231–242
35. Day NL, Richardson GA (1991) Prenatal marijuana use: epidemiology, methodologic issues, and infant outcome. Clin Perinatol 18(1):77–91
36. Fried PA, O’Connell CM (1987) A comparison of the effects of prenatal exposure to tobacco, alcohol, cannabis and caffeine on birth size and subsequent growth. Neurotoxicol Teratol 9(2):79–85
37. Burns JK (2013) Pathways from cannabis to psychosis: a review of the evidence. Front Psychiatry 4:128
38. Weiser M, Noy S (2005) Interpreting the association between cannabis use and increased risk for schizophrenia. Dialogues Clin Neurosci 7(1):81–85
39. Fried PA (1980) Marihuana use by pregnant women: neurobehavioral effects in neonates. Drug Alcohol Depend 6(6):415–424
40. Fried PA, Watkinson B, Gray R (1998) Differential effects on cognitive functioning in 9- to 12-year olds prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol 20(3):293–306
41. Hofman A et al (2004) Growth, development and health from early fetal life until young adulthood: the Generation R Study. Paediatr Perinat Epidemiol 18(1):61–72
42. Jaddoe VW et al (2012) The generation R Study: design and cohort update 2012. Eur J Epidemiol 27(9):739–756
43. El Marroun H et al (2008) Demographic, emotional and social determinants of cannabis use in early pregnancy: the generation R study. Drug Alcohol Depend 98(3):218–226
44. El Marroun H et al (2009) Intrauterine cannabis exposure affects fetal growth trajectories: the generation R Study. J Am Acad Child Adolesc Psychiatry 48(12):1173–1181
45. Hadlock FP et al (1984) Sonographic estimation of fetal weight. The value of femur length in addition to head and abdomen measurements. Radiology 150(2):535–540
46. Zuckerman B et al (1989) Effects of maternal marijuana and cocaine use on fetal growth. N Engl J Med 320(12):762–768
47. Boito S et al (2002) Umbilical venous volume flow in the normally developing and growth-restricted human fetus. Ultrasound Obstet Gynecol 19(4):344–349
48. El Marroun H et al (2010) A prospective study on intrauterine cannabis exposure and fetal blood flow. Early Hum Dev 86(4):231–236
49. Fried PA, Watkinson B (1990) 36- and 48-month neurobehavioral follow-up of children prenatally exposed to marijuana, cigarettes, and alcohol. J Dev Behav Pediatr 11(2):49–58
50. Huizink AC, Mulder EJ (2006) Maternal smoking, drinking or cannabis use during pregnancy and neurobehavioral and cognitive functioning in human offspring. Neurosci Biobehav Rev 30(1):24–41
51. Richardson GA, Day NL, Goldschmidt L (1995) Prenatal alcohol, marijuana, and tobacco use: infant mental and motor development. Neurotoxicol Teratol 17(4):479–487
52. Wang X et al (2004) In utero marijuana exposure associated with abnormal amygdala dopamine D2 gene expression in the human fetus. Biol Psychiatry 56(12):909–915
53. Goldschmidt L et al (2004) Prenatal marijuana and alcohol exposure and academic achievement at age 10. Neurotoxicol Teratol 26(4):521–532
54. Fried PA, Watkinson B, Gray R (1992) A follow-up study of attentional behavior in 6-year-old children exposed prenatally to marihuana, cigarettes, and alcohol. Neurotoxicol Teratol 14(5):299–311
55. Goldschmidt L, Day NL, Richardson GA (2000) Effects of prenatal marijuana exposure on child behavior problems at age 10. Neurotoxicol Teratol 22(3):325–336
56. Leech SL et al (1999) Prenatal substance exposure: effects on attention and impulsivity of 6-year-olds. Neurotoxicol Teratol 21(2):109–118
57. Trezza V, Cuomo V, Vanderschuren LJ (2008) Cannabis and the developing brain: insights from behavior. Eur J Pharmacol 585(2–3):441–452
58. Trivedi JK (2006) Cognitive deficits in psychiatric disorders: current status. Indian J Psychiatry 48(1):10–20
59. Smith AM et al (2006) Effects of prenatal marijuana on visuospatial working memory: an fMRI study in young adults. Neurotoxicol Teratol 28(2):286–295
60. Navarro M, Rubio P, de Fonseca FR (1995) Behavioural consequences of maternal exposure to natural cannabinoids in rats. Psychopharmacology 122(1):1–14
61. Mereu G et al (2003) Prenatal exposure to a cannabinoid agonist produces memory deficits linked to dysfunction in hippocampal long-term potentiation and glutamate release. Proc Natl Acad Sci USA 100(8):4915–4920
62. Trezza V et al (2012) Altering endocannabinoid neurotransmission at critical developmental ages: impact on rodent emotionality and cognitive performance. Front Behav Neurosci 6:2
63. Szutorisz H et al (2014) Parental THC exposure leads to compulsive heroin-seeking and altered striatal synaptic plasticity in the subsequent generation. Neuropsychopharmacology
64. Day NL et al (1994) Effect of prenatal marijuana exposure on the cognitive development of offspring at age three. Neurotoxicol Teratol 16(2):169–175
65. Herkenham M (1992) Cannabinoid receptor localization in brain: relationship to motor and reward systems. Ann N Y Acad Sci 654:19–32
66. Matsuda LA et al (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346(6284):561–564
67. Morgan NH, Stanford IM, Woodhall GL (2009) Functional CB2 type cannabinoid receptors at CNS synapses. Neuropharmacology 57(4):356–368
68. Lauckner JE et al (2008) GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 105(7):2699–2704
69. Sawzdargo M et al (1999) Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res 64(2):193–198
70. Cabral GA et al (2008) CB2 receptors in the brain: role in central immune function. Br J Pharmacol 153(2):240–251
71. Kaplan BL (2013) The role of CB1 in immune modulation by cannabinoids. Pharmacol Ther 137(3):365–374
72. den Boon FS et al (2012) Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors. Proc Natl Acad Sci USA 109(9):3534–3539
73. Van Sickle MD et al (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310(5746):329–332
74. Belue RC et al (1995) The ontogeny of cannabinoid receptors in the brain of postnatal and aging rats. Neurotoxicol Teratol 17(1):25–30
75. Oh HA et al (2013) Uncovering a role for endocannabinoid signaling in autophagy in preimplantation mouse embryos. Mol Hum Reprod 19(2):93–101
76. Keimpema E, Mackie K, Harkany T (2011) Molecular model of cannabis sensitivity in developing neuronal circuits. Trends Pharmacol Sci 32(9):551–561
77. Berrendero F et al (1998) Localization of mRNA expression and activation of signal transduction mechanisms for cannabinoid receptor in rat brain during fetal development. Development 125(16):3179–3188
78. Bisogno T et al (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 163(3):463–468
79. Wang X et al (2003) Preferential limbic expression of the cannabinoid receptor mRNA in the human fetal brain. Neuroscience 118(3):681–694
80. Devane WA et al (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258(5090):1946–1949
81. Stella N, Schweitzer P, Piomelli D (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature 388(6644):773–778
82. Hillard CJ, Campbell WB (1997) Biochemistry and pharmacology of arachidonylethanolamide, a putative endogenous cannabinoid. J Lipid Res 38(12):2383–2398
83. Cravatt BF et al (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384(6604):83–87
84. Dinh TP et al (2002) Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 99(16):10819–10824
85. Gulyas AI et al (2004) Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci 20(2):441–458
86. Di Marzo V et al (1998) Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 21(12):521–528
87. Harkany T et al (2007) The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol Sci 28(2):83–92
88. Paria BC et al (2001) Dysregulated cannabinoid signaling disrupts uterine receptivity for embryo implantation. J Biol Chem 276(23):20523–20528
89. Psychoyos D et al (2012) Cannabinoid receptor 1 signaling in embryo neurodevelopment. Birth Defects Res B Dev Reprod Toxicol 95(2):137–150
90. Berghuis P et al (2007) Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science 316(5828):1212–1216
91. Argaw A et al (2011) Concerted action of CB1 cannabinoid receptor and deleted in colorectal cancer in axon guidance. J Neurosci 31(4):1489–1499
92. Harkany T et al (2008) Endocannabinoid functions controlling neuronal specification during brain development. Mol Cell Endocrinol 286((1-2 Suppl 1)):S84–S90
93. Keimpema E et al (2010) Differential subcellular recruitment of monoacylglycerol lipase generates spatial specificity of 2-arachidonoyl glycerol signaling during axonal pathfinding. J Neurosci 30(42):13992–14007
94. Kim D, Thayer SA (2001) Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture. J Neurosci 21(10):RC146
95. Burstein S et al (1994) Phospholipase participation in cannabinoid-induced release of free arachidonic acid. Biochem Pharmacol 48(6):1253–1264
96. Bari M et al (2006) New insights into endocannabinoid degradation and its therapeutic potential. Mini Rev Med Chem 6(3):257–268
97. Coutts AA et al (2001) Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons. J Neurosci 21(7):2425–2433
98. Mulder J et al (2008) Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. Proc Natl Acad Sci USA 105(25):8760–8765
99. Puighermanal E et al (2009) Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling. Nat Neurosci 12(9):1152–1158
100. Tanimura A et al (2010) The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. Neuron 65(3):320–327
101. Keimpema E et al (2013) Nerve growth factor scales endocannabinoid signaling by regulating monoacylglycerol lipase turnover in developing cholinergic neurons. Proc Natl Acad Sci USA 110(5):1935–1940
102. Kittler JT et al (2000) Large-scale analysis of gene expression changes during acute and chronic exposure to [Delta]9-THC in rats. Physiol Genomics 3(3):175–185
103. Grigorenko E et al (2002) Assessment of cannabinoid induced gene changes: tolerance and neuroprotection. Chem Phys Lipids 121(1–2):257–266
104. Perez-Rosado A et al (2000) Prenatal Delta(9)-tetrahydrocannabinol exposure modifies proenkephalin gene expression in the fetal rat brain: sex-dependent differences. Brain Res Dev Brain Res 120(1):77–81
105. Gomez M, Hernandez M, Fernandez-Ruiz J (2007) The activation of cannabinoid receptors during early postnatal development reduces the expression of cell adhesion molecule L1 in the rat brain. Brain Res 1145:48–55
106. Quinn HR et al (2008) Adolescent rats find repeated Delta(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology 33(5):1113–1126
107. DiNieri JA et al (2011) Maternal cannabis use alters ventral striatal dopamine D2 gene regulation in the offspring. Biol Psychiatry 70(8):763–769
108. Campolongo P et al (2007) Perinatal exposure to delta-9-tetrahydrocannabinol causes enduring cognitive deficits associated with alteration of cortical gene expression and neurotransmission in rats. Addict Biol 12(3–4):485–495
109. Tortoriello G et al (2014) Miswiring the brain: Delta9-tetrahydrocannabinol disrupts cortical development by inducing an SCG10/stathmin-2 degradation pathway. EMBO J 33(7):668–685
110. Morozov YM, Ben-Ari Y, Freund TF (2004) The spatial and temporal pattern of fatty acid amide hydrolase expression in rat hippocampus during postnatal development. Eur J Neurosci 20(2):459–466